Lenalidomide was also recently reported to inhibit IL-6-mediated STAT3 phosphorylation in NK cells (41), decrease CXCL12 expression by CLL stroma cells, and impair CLL response to CXCL12 (54, 55). Here, CXCL12 is linked to B-cell chronic lymphocytic leukemia.